Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Want to see ALNY full AI Analyst Report?
ALNY Stock Chart & Stats
$309.66
-$0.58(-0.25%)
At close: 4:00 PM EST
$309.66
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$273.11 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.10M
Market Cap
$37.13B
Enterprise Value$37.31B
Total Cash (Recent Filing)$3.01B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)64.0
Beta0.88
Next Earnings
Jul 30, 2026EPS Estimate
1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.36
Shares Outstanding133,512,570
10 Day Avg. Volume1,318,194
30 Day Avg. Volume1,101,107
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue8.70
Enterprise Value/Gross Profit10.76
Enterprise Value/Ebitda40.36
Forecast
1Y Price Target
$456.07Price Target Upside47.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)7.49
Revenue Forecast (FY)$5.61B
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationSustained TTM operating cash flow and strong free cash flow growth materially reduce Alnylam's dependence on external financing. Robust cash generation supports continued heavy R&D investment, commercial launches and debt servicing, increasing the firm's durable ability to fund pipeline progression and strategy execution.
Profitability Inflection And MarginsThe shift to sustained profitability and positive EBIT across trailing twelve months signals scalable commercialization of RNAi products. Durable margins and earnings reduce dilution risk, provide internal funding for growth initiatives, and demonstrate operational leverage that can support long-term investment in new indications and geographic expansion.
Strong TTR Commercial Franchise And AdoptionRapid TTR revenue growth, expanding prescriber base and high real-world adherence reflect durable clinical and payer acceptance. A deep, sticky commercial franchise in rare disease supports predictable recurring revenue, facilitates lifecycle extension and strengthens negotiating leverage with payors and partners over multiple years.
Bears Say
Rising Royalty Pressure On Gross MarginsHigher, sales-linked royalty rates create a structural headwind to product-level gross margins as volumes grow. This recurring margin pressure reduces operating leverage from top-line growth, compresses free cash flow conversion and can materially affect long-term profitability unless offset by price, mix or lower COGS.
Moderate Leverage And Prior Equity WeaknessElevated leverage and a history of very low equity constrain financial flexibility and raise sensitivity to profit deterioration or higher rates. While improved, the balance sheet can quickly tighten if earnings reverse, increasing refinancing and covenant risk and limiting capital allocation optionality for strategic moves.
Rising Operating Investments And Revenue VariabilitySteep increases in R&D and SG&A raise the break-even revenue threshold and amplify execution risk if commercial growth lags. Simultaneously, milestone-driven collaboration revenue is volatile, reducing predictability of cashflow. Together, these factors heighten sensitivity of margins and funding needs over the medium term.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $273.11 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $37.13B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 38 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Apr 30, 2026. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $0.872 by $0.638.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.63.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 133,512,570 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.51 in its last earnings report, beating expectations of $0.872. Following the earnings report the stock price went up 2.756%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$456.07 (47.28% Upside)
$456.07 (47.28% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 263.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $519.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.95%
12-Months-Change
Fundamentals
Return on Equity
98.29%
Trailing 12-Months
Asset Growth
21.73%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong commercial and financial quarter highlighted by record product revenues, robust TTR franchise growth, profitability and substantial pipeline progress including accelerated Phase III enrollment and supportive real-world evidence. Challenges noted were margin pressure from rising royalties, higher R&D/SG&A investments, an expected Germany pricing adjustment that transiently impacted international results, and typical seasonal/operational phasing headwinds. Management reiterated full-year guidance and communicated confidence in ongoing launch dynamics and pipeline execution, while acknowledging competitive and timing uncertainties.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$456.07
▲(47.28% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
44.38% Mutual Funds
31.66% Other Institutional Investors
1.30% Public Companies and Individual Investors